Arylated Fenchone Derivatives for Selective CB2 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammation, pain, autoimmune diseases, and neurodegenerative disorders often have adverse psychotropic effects and limited efficacy, particularly due to the activation of CB1 receptors, which are associated with central nervous system effects.
Innovation Solution
Development of novel bicyclic monoterpenoid fenchone derivatives with specific alkylresorcinol and alkylphenol groups that selectively target CB2 receptors, acting as CB2 receptor agonists to modulate inflammatory and immune responses without the psychotropic effects of CB1 receptor activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CB1 receptor activation is used to treat inflammation and pain, then anti-inflammatory and analgesic effects are achieved, but psychotropic side effects occur
Solution Approach 1:
The invention segments the cannabinoid receptor system by designing compounds that selectively target only CB2 receptors while excluding CB1 receptors. This segmentation allows the therapeutic effects mediated by CB2 (anti-inflammatory, analgesic) to be achieved without the psychotropic side effects associated with CB1 activation, effectively separating the desirable from the undesirable physiological responses.
Solution Approach 2:
The compound introduces local quality differentiation through selective receptor binding. The molecular structure is optimized to possess specific structural features (such as the 2,5-disubstituted resorcinol moiety with particular substituents) that confer selectivity for CB2 receptors over CB1 receptors, enabling the compound to exert its pharmacological effects locally at peripheral immune cells and inflammatory sites without affecting central nervous system CB1 receptors.
2Object-affected harmful factors
If conventional anti-inflammatory treatments are used, then inflammation is reduced, but adverse psychotropic effects and limited efficacy occur
Solution Approach 1:
The invention introduces a selective CB2 agonist as an intermediary substance that mediates the anti-inflammatory response through a specific pathway. Rather than using conventional anti-inflammatory drugs with broad mechanisms and side effects, the compound acts as a selective mediator that activates CB2 receptors on immune cells, triggering anti-inflammatory cascades (such as inhibition of NF-κB, reduction of pro-inflammatory cytokines) without affecting other physiological systems, thereby improving the therapeutic profile.
3Object-affected harmful factors
If CB2 selective agonists are developed, then psychotropic side effects are avoided, but compound complexity increases
Solution Approach 1:
The invention achieves CB2 selectivity through parameter changes in the molecular structure, specifically in the substituents of the 2,5-disubstituted resorcinol core. By varying parameters such as the type (alkyl, alkenyl, alkynyl, halogen), position, and chain length of substituents, the compound's affinity and selectivity for CB2 receptors are optimized. These parameter adjustments allow fine-tuning of the pharmacological profile to achieve high CB2 selectivity while managing molecular complexity.
Data Source
AI summary
The present invention provides arylated fenchone derivatives, compositions comprising them, processes for their preparation and uses thereof.